Short-burst oxygen therapy in chronic obstructive pulmonary disease  by O’Neill, Brenda et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 1129–11380954-6111/$ - s
doi:10.1016/j.r
Correspondi
E-mail addrEVIDENCE-BASED REVIEW
Short-burst oxygen therapy in chronic obstructive
pulmonary disease
Brenda O’Neilla,, Joe Mac Mahonb, Judy Bradleya,baHealth & Rehabilitation Research Institute, School of Health Sciences, University of Ulster,
Shore Rd Newtownabbey, Co Antrim, BT37 OQB, Northern Ireland
bRegional Respiratory Centre, Belfast City Hospital, Lisburn Rd, Belfast, BT97AB, Northern Ireland
Received 14 January 2005; accepted 31 March 2006KEYWORDS
Short-burst oxygen
therapy;
Systematic reviewee front matter & 2006
med.2006.03.038
ng author. Tel.: +44 289
ess: b.oneill@ulster.ac.Summary
Introduction: Despite widespread prescription, the efficacy of short-burst oxygen
therapy has not been established.
Aim: To systematically review the available evidence for short-burst oxygen therapy
in patients with chronic obstructive pulmonary disease (COPD).
Method: Retrieval of randomized-controlled trials comparing short-burst oxygen
(oxygen for breathlessness at rest, before exercise and after exercise) with placebo
in patients with COPD. Data were extracted and, where possible, outcome measures
were combined using RevMan analyses 4.2. The methodological quality of each trial
was assessed using the PEDro scale.
Results: Studies differed in the type of exercise test used, the amount of oxygen
delivered and in the length of time for pre- or post-dosing. Quality of the included
studies as rated by the PEDro scale was good. For many outcome measures, data
could not be pooled for meta-analysis. Short-burst oxygen is primarily indicated for
the symptomatic relief of breathlessness, and the bulk of evidence from this review
suggests that short-burst oxygen therapy does not reduce breathlessness. For
secondary outcome measures (exercise capacity, oxygen saturation [SaO2], other
ventilatory parameters), the results are not consistent.
Conclusion: The studies in this review suggest that the widespread prescription of
short-burst oxygen is not evidence-based. If prescription is to continue, the scientific
rationale for short-burst oxygen therapy must be established.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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uk (B. O’Neill).
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B. O’Neill et al.1130Introduction nosis were excluded, unless the results of patientsDomiciliary oxygen has been categorized as long-
term oxygen therapy (LTOT), ambulatory oxygen
therapy and short-burst (intermittent) oxygen ther-
apy.1,2 The evidence for LTOTand ambulatory oxygen
in chronic obstructive pulmonary disease (COPD) has
been summarized in Cochrane systematic reviews
and published in the Cochrane Library.3–5
The evidence examining short-burst oxygen ther-
apy has not been systematically reviewed. Short-
burst oxygen therapy has been defined as the
intermittent use of oxygen for the relief of breath-
lessness, before or for recovery after exercise.1 It is
recommended for episodic breathlessness not re-
lieved by other treatments and is used by patients
particularly after exercise.1,2,6 Short-burst oxygen
therapy is usually prescribed by oxygen cylinders and
often for patients with COPD.7,8 The physiological
mechanisms by which improvement might take place
with short-burst oxygen are not clear, yet prescrip-
tion is widespread and costly.6,9,10
The aim of this review was to systematically
review the available evidence for short-burst
oxygen therapy in patients with COPD.Methods
The methods used in this review fulfill the criteria
outlined in the QUOROM statement for reporting of
systematic reviews.11
Selection of studies
Electronic searches of Medline, Cinhal, and EMBASE
were conducted using the following search terms:
COPD (or bronchitis or emphysema) AND (oxygen
OR short-burst oxygen OR intermittent oxygen OR
short-term oxygen) AND (breathlessness OR exer-
cise OR exercise test) (last search April 2005).
Electronic websites of the key respiratory journals
were searched. All databases were searched for
full-text articles from their inception up until April
2005 and in the English language. The reference
lists of each included article, as well as any review
articles found, were then searched for further
randomized-controlled trials (RCTs).
Interventions and participants
RCTs were retrieved that compared short-burst
oxygen (oxygen at rest, before exercise or activity,
after exercise or activity) with placebo in patients
with COPD. Studies with mixed respiratory diag-with COPD were analyzed separately.
Outcome measures
The primary outcome measure was breathlessness;
secondary outcome measures included exercise
capacity, oxygen saturation (SaO2) and other
ventilatory parameters e.g. ventilation [VE], oxy-
gen consumption [VO2], inspiratory capacity [IC], or
patient preference.
Methods of the review
The methodological quality of each trial was
independently assessed by two reviewers (BO’N,
JB) using the PEDro scale.12 The PEDro scale scores
studies out of 10, and has been shown to be a
reliable measure of study quality.13 Data from the
trials were extracted using a standard data-
acquisition form.
Statistical analysis
Where possible, trial data for primary and second-
ary outcome measures were combined using Rev-
Man analyses 4.2.14 This may not have been
possible if (1) data were only available for a single
study; (2) there were insufficient data to be
entered into RevMan, and (3) there were differ-
ences in the reporting of results. In these cases, the
results of the original analyses from the trial were
presented. Data for submaximal and maximal tests
were entered separately. Owing to the crossover
design of the studies, data were entered as generic
inverse variance data. A random- or fixed-effects
model was used depending upon the level of
statistical heterogeneity observed.15
Description of studies
The trial flow and the meta-analysis profile as
outlined in the QUOROM statement for reporting of
systematic reviews is shown in Fig. 1.
Study characteristics and quality
Eight studies were identified that met the inclusion
criteria (Table 1). All studies used a crossover
design for allocation to oxygen and placebo. Three
were double-blind studies16–18 and four were single
blind,19–22 and blinding was not reported in one
study.23 Drop-outs were reported in three stu-
dies,16,19,22 but this did not affect the data
extracted for this review. Studies used a variety
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RCTs identified and 
screened for 
retrieval
(n = 10) 
RCTs excluded (n = 2) 
• Study population were 
hospital inpatients and 
likely not stable 24,25
Potentially appropriate
RCT to be included in
meta-nalysis (total = 8): 
pre-dosing (n = 5); post-
dosing (n = 6) RCTs excluded from the meta-
analysis: post-dosing (n = 2) 
• Outcome measurements taken 
at different time points or 
uncomparable measurement 
or result 20,22
RCTS included in 
the meta-analysis: 
pre-dosing (n = 2); 
post-dosing (n = 4)
RCTs withdrawn by outcome: post-
dosing
• Breathlessness (n =  1) no 
data on rate of return 
breathlessness 16
• SaO2 (n= 2 ) no data 21,23
• HR (n= 2) no data 19, 21
RCTs withdrawn by outcome: pre- 
dosing (n = 0)
RCTs with usable information by 
outcome: post-dosing
• Breathlessness (n = 3) 19,21,23
• SaO2 (n = 2) 16,19
• HR (n = 2) 16,23 
RCTs with usable information by 
outcome: pre-dosing
• Exercise capacity (n = 2) 16,19
RCTs excluded from the meta-
analysis: pre dosing (n = 3)
• Outcome measurements taken 
at different time points or 
uncomparable measurement or 
result 17,20
• no data available 18
Figure 1 Trial flow and meta-analysis profile as outlined in the QUOROM statement for reporting of systematic
reviews.11
Short-burst oxygen therapy in COPD 1131of exercise tests and oxygen levels to assess the
effectiveness of oxygen (Table 1). PEDro scores are
reported in Table 1, and all studies scored six or
more out of 10.Results
The overall results are summarized in Table 2. Data
from the pooled analysis are presented in Figs. 2
and 3.
Oxygen at rest
No studies assessing the effects of oxygen at rest
met the inclusion criteria.Pre-dosing studies (n ¼ 5)
Primary outcome measure: breathlessness
All five studies assessed breathlessness.16–20 Mea-
surements were taken at different time points
relevant to pre-dosing, and were not consistent
between studies. One study measured the change
in breathlessness score at the end of the test;16 one
study measured breathlessness at isotime17; one
study provided no data18; the final breathless-
ness score was measured in one study19; and one
study measured the maximum breathlessness
score that occurred during the study.20 Except in
the study by Woodcock et al.18 (maximal tread-
mill test only), data from the original studies
showed no significant benefit from pre-dosing with
oxygen.16–20
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Table 2 Summary of key results.
General For the primary outcome measure of breathlessness there is evidence of no benefit from oxygen
compared to placebo except in one study, which assessed pre dosing. For secondary outcome
measures the results are not conclusive
Pre-dosing Breathlessness—There is evidence from 5 original studies that breathlessness is not
significantly reduced and from 1 original study that breathlessness is significantly reduced
Exercise tolerance—Distance: there is evidence from pooled analysis and from 1 additional
study that exercise distance is significantly increased with submaximal tests with oxygen
compared to placebo. There is evidence from 1 study that maximal exercise distance is
increased and from 1 original study that maximal exercise distance is not increased with oxygen
compared to placebo. Duration: There is evidence form 2 studies that the duration of exercise
is not significantly increased with oxygen compared to placebo
SaO2—The timing of measurement of SaO2 was not consistent and the results are not conclusive
Other—There is evidence from single studies that HR, return to baseline HR, subjective
recovery rate and patient preference are not improved by oxygen
Post-dosing Breathlessness—There is evidence from 3 original studies that breathlessness at the end of post
dosing is not reduced. There is evidence from pooled analysis of submaximal tests studies, and
from one maximal test study that the rate of return to baseline breathlessness is not
significantly reduced with oxygen compared to placebo
SaO2—There is evidence from 1 study that maximum change in SaO2 is increased with oxygen
and from 1 study that SaO2 at the end of the post-dosing test is increased with oxygen. There is
evidence from pooled analysis of submaximal tests that the rate of return to baseline SaO2 is
not significantly improved with oxygen
Other—There is evidence from pooled analysis of submaximal test studies that the rate of
return to baseline HR is not significantly reduced with oxygen. There is evidence from 1 study
that the time for resolution of dynamic hyperinflation is reduced with oxygen compared to
placebo. There is evidence from single original studies that VE, RR, rate of return of RR, and
rate of return to subjective recovery is not significantly reduced with submaximal tests with
oxygen compared to placebo
Review: Short burst oxygen therapy (SBOT copy without maximal)
Comparison: 02 Pre dosing studies                                                                                         
Outcome: 01 Exercise distance                                                                                          
Study  Treatment  Control  metres (fixed)  Weight  metres (fixed)
or sub-category N N  metres (SE)  95% CI  %  95% CI
02 Sub maximal
Nandi 2003                34                           34      5.0000 (2.7800)  80.51      5.00 [-0.45, 10.45]     
Lewis 2003                22                           22     10.1000 (5.6500)  19.49     10.10 [-0.97, 21.17]     
Subtotal (95% CI)       56                           56 100.00      5.99 [1.11, 10.88]
Test for heterogeneity: Chi² = 0.66, df = 1 (P = 0.42), I² = 0%
Test for overall effect: Z = 2.40 (P = 0.02)
Total (95% CI)       56                           56 100.00      5.99 [1.11, 10.88]
Test for heterogeneity: Chi² = 0.66, df = 1 (P = 0.42), I² = 0%
Test for overall effect: Z = 2.40 (P = 0.02)
 -100  -50  0  50  100
 Favours air  Favours oxygen
Figure 2 Pre-dosing: exercise distance.
B. O’Neill et al.1134Secondary outcome measure: exercise capacity
All five studies assessed exercise capacity.16–20 Four
studies reported on exercise distance, and two of
these studies that used submaximal tests had data
in a usable format for meta-analysis (Fig. 2).16,19 No
significant heterogeneity was found between the
studies (I2 0%). Pre-dosing with oxygen significantly
improved distance (WMD) 5.99m (95% CI
1.11–10.88) (n ¼ 56). One study that did not reportdata in a usable format for meta-analysis reported
a significant improvement in both treadmill and
6-min Walk Test distance,18 and one study that used
a maximal test reported no significant improve-
ment in exercise distance when pre-dosing with
oxygen.17
Two studies reported on duration of exercise
and showed no significant increase in exercise
duration.17,20
ARTICLE IN PRESS
Review: Short burst oxygen therapy (SBOT copy without maximal)
Comparison: 01 Post dosing studies                                                                                        
Outcome: 04 Time for breathlessness to return to baseline                                                              
Study  Treatment  Control  seconds (fixed)  Weight  seconds (fixed)
or sub-category N N  seconds (SE)  95% CI  %  95% CI
01 submaximal
Evans 1986                19                     19    -36.0000 (17.4100)   4.08    -36.00 [-70.12, -1.88]    
Maques-magelles           18                     18    -40.0000 (12.0400)   8.52    -40.00 [-63.60, -16.40]   
Lewis 2003                22                     22      2.1000 (3.7600)  87.40      2.10 [-5.27, 9.47]      
Subtotal (95% CI)       59                     59 100.00     -3.04 [-9.93, 3.85]
Test for heterogeneity: Chi² = 14.88, df = 2 (P = 0.0006), I² = 86.6%
Test for overall effect: Z = 0.87 (P = 0.39)
Total (95% CI)       59                     59 100.00     -3.04 [-9.93, 3.85]
Test for heterogeneity: Chi² = 14.88, df = 2 (P = 0.0006), I² = 86.6%
Test for overall effect: Z = 0.87 (P = 0.39)
 -100  -50  0  50  100
 Favours oxygen  Favours air
Figure 3 Post-dosing: time for breathlessness to return to baseline.
Short-burst oxygen therapy in COPD 1135Secondary outcome measure: SaO2
SaO2 was assessed in four out of five stu-
dies.16,17,19,20 Data from the original studies was
inconsistent and reported the following: three
studies measured SaO2 at the end of the pre-dosing
period and found that SaO2 was significantly
increased by breathing oxygen16,17,19; one study
measured the mean fall in SaO2 at the end of
exercise and found no significant improvement with
oxygen16; one study measured the maximum
change in SaO2 compared with rest, and found that
SaO2 was significantly increased with oxygen
20; two
studies measured SaO2 at the end of the test and
found no significant increase with oxygen16,17; and
one study measured the rate of recovery of SaO2 to
baseline and found this was not significantly
reduced with oxygen.16Other outcome measures
Other outcome measures were reported in three
studies: maximum heart rate,17 rate of return to
baseline heart rate,16 subjective recovery rate,16
and patient preference.20 Data from each of the
original studies showed no significant difference in
any of these outcome measures with oxygen
compared with placebo.Post-dosing studies (n ¼ 6)
Primary outcome measure: breathlessness
Breathlessness was reported in all six stu-
dies.16,19–23 Measurements were taken at different
time points relevant to post-dosing, and were not
consistent between studies. One study measured
breathlessness at the end of the post-dosing
period16; one study measured the maximal breath-
lessness score during the study20; and the mean
breathlessness score during the recovery period
was reported in one study.22 Data from the originalstudies showed no significant reduction in breath-
lessness.
The rate of return to baseline breathlessness was
reported in four studies. Three submaximal test
studies reported on the rate of return to baseline
breathlessness (Fig. 3).19,21,23 There was significant
heterogeneity (I2 86.6%) between the studies. Post-
dosing with oxygen did not significantly reduce the
rate of return to baseline breathlessness with
random-effects modelling (WMD 22.42 s, 95% CI
55.18 to 10.34) (n ¼ 59). It was noted that the
original paper by Marques-Magallanes21 reported no
significant difference in the rate of return of
breathlessness, but a significant difference was
reported between the order of the exercise tests.
When the data were entered in as a mean
difference and associated standard error, the study
effect estimate showed a difference in favour of
oxygen (Fig. 3).21 Although, the RevMan study
effect estimate was in conflict with the original
paper, when the data from Marques-Magallanes21
was removed, no change was found in the overall
estimate of effect. This may reflect certain
difficulties with crossover studies, whereby carry-
over or order effects can distort the findings of a
study. One maximal test study reported on the rate
of return to baseline breathlessness, and data from
the original study reported that oxygen did not
significantly reduce the rate of return to baseline
breathlessness.22
Secondary outcome measures: SaO2
SaO2 was assessed in three out of six studies.
16,19,20
SaO2 at the end of the post-dosing test was
reported in one study,16 and the maximum change
in SaO2 compared with rest was reported in one
study20; data from both original studies reported a
significant increase in SaO2 with oxygen.
16,20 The
rate of return to baseline SaO2 was reported in two
studies using submaximal exercise tests.16,19 There
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(I2 74.1%). Post-dosing with oxygen did not sig-
nificantly reduce the rate of return to baseline SaO2
with random-effects modelling (WMD 4.94 (95% CI
92.60 to 82.72) (n ¼ 40).
Other outcome measures
The rate of return to baseline heart rate was
reported in two studies using submaximal exercise
tests.16,23 No significant heterogeneity was found
between the studies (I2 28.1%). Post-dosing with
oxygen did not significantly reduce the rate of
return to baseline heart rate with fixed-effects
modelling (WMD 15.86 s, 95% CI 49.36 to 81.08)
(n ¼ 37). The rate of return to baseline inspiratory
capacity was reported in one study, and data from
the original study showed no significant improve-
ment with oxygen.22
Additional outcome measures were reported by
four studies: VE during recovery,
22 rate of return of
RR to baseline,23 rate of return to baseline
subjective recovery,16 patient preference.20 Data
from each of the original studies showed no
significant difference in oxygen.Discussion
In this review, the available evidence is summar-
ized for short-burst oxygen therapy (oxygen at rest,
before exercise and oxygen after exercise) in
patients with COPD. The studies in this review of
good quality trials suggest that the widespread
prescription of short-burst oxygen is currently not
evidence-based. Short-burst oxygen is primarily
indicated for the symptomatic relief of breath-
lessness, and the bulk of evidence from this review
suggests that short-burst oxygen therapy does not
reduce breathlessness. For secondary outcome
measures, the results are not consistent. Where
improvements with oxygen compared with air have
been shown with pooled analysis, the reported
effect size may not be clinically relevant, and this
warrants further clarification.
Oxygen at rest
We were unable to identify any evidence to support
the use of oxygen given at rest for patients with
COPD who are stable. This absence of evidence
cannot be interpreted as evidence of no effect. Two
studies that examined the effects of short-burst
oxygen compared with air at rest were excluded, as
some or all of the patients were hospital inpatients
and unlikely to be stable.24,25Pre-dosing studies
Data from the original studies showed no significant
reduction in breathlessness in any study except for
the study by Woodcock et al.18 (treadmill test),
which provided no data for meta-analysis. Although
the study by Woodcock et al.18 scored high on the
quality scale, the sample size was small (n ¼ 10)
and, despite the multiple tests in the study, the
possibility of a period effect, carry-over effect, or
both, was not investigated.
The significant improvement when pre-dosing
with oxygen in submaximal exercise distance could
support the use of oxygen before exercise and
activity, but the small effect size reported may not
be clinically important. The effect of pre-dosing
with oxygen on SaO2 was not determinable. As the
relationship of desaturation to breathlessness has
been shown to be variable, the resolution of
desaturation may be less relevant if short-burst
oxygen therapy is primarily used to relieve breath-
lessness.26–28
Post-dosing studies
Short-burst oxygen is primarily used to relieve
breathlessness after exercise and activity,6 and the
results of this review provide consistent evidence
that short-burst oxygen is not effective in reducing
breathlessness after exercise or activity. The
importance of the relationship of SaO2 and breath-
lessness remains controversial. Although the SaO2
was improved with oxygen compared with placebo
when post-dosing with oxygen, the rate of return to
baseline SaO2 was not improved with oxygen. It is
not clear whether the physiological increase in
SaO2 is more relevant than the speed to recovery of
SaO2.
Only one study reported a significant improve-
ment in the time for resolution to baseline
inspiratory capacity with oxygen compared with
placebo.22 A similar reduction in dynamic hyperin-
flation has been proposed as one mechanism for the
efficacy of ambulatory oxygen,29 and these physio-
logical measurements may be important outcomes
that could be included in any future studies on
short-burst oxygen.
Proposed mechanisms of action
The physiological mechanisms by which improve-
ment might take place with short-burst oxygen are
not clear. Oxygen may depress ventilation, so
reducing breathlessness, but this could be at the
expense of CO2 retention. Total oxygen stores in
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100% oxygen has proven useful in anaesthetic
practice, where it allows a safe period of apnoea.
However, 30% (about 3 l/min) oxygen, as might be
provided by nasal cannula, could conceivably
increase the stores by 70ml in the normoxaemic
individual. In a patient with a subnormal resting
arterial haemoglobin saturation of 90%, an addi-
tional increase of 80ml might be expected.30
Compared with the oxygen cost of exercise, which
is about 1 l/min for a normal walking pace, the
potential increase in oxygen stores is small. Pre-
oxygenation would not be expected to produce a
marked physiological benefit.
It is possible that post-dosing with oxygen
produces similar mechanisms to that proposed for
ambulatory oxygen, such as reduction of ventila-
tion and respiratory rate, improved oxygen uptake
by peripheral muscles, decreased carotid chemor-
eceptor stimulation and a reduction in dynamic
hyperinflation.26,29,31–33 One study in this review
provides some support for this, and reported a
significant increase in inspiratory capacity and
reduction in dynamic hyperinflation with oxygen
given for 15min after maximal exercise testing.22Limitations
Most studies in this review provide information on
the level of homogeneity of the patients in relation
to disease severity, age and gender. Few of the
trials categorized patients at baseline according to
the level of hypoxaemia or exercise-induced
desaturation, so some trials may have included
patients who met the criteria for LTOT or ambula-
tory oxygen therapy, respectively. This could
introduce bias as these patients are not recom-
mended short-burst oxygen and may not represent
the population of interest.1,2 The inclusion of
patients who meet the criteria for LTOT or
ambulatory oxygen therapy could over- or under-
estimate the effects of short-burst oxygen.
There was no consistency in amount of oxygen
delivered, the method of oxygen delivery, the
length of time for pre- and post-dosing and the
type of exercise tests used among the studies in this
review; therefore comparisons are difficult. Out-
come assessment was not consistent among studies,
making it difficult to pool data or compare studies.
The clinical relevance of, for example, the rate of
resolution of breathlessness may be more impor-
tant than the actual breathlessness score reported
after exercise. Future studies should consider the
use of validated, reliable and responsive outcomemeasures that can detect clinical importance as
well as statistical change.
All the studies in this review used a crossover
design, but not all used statistical analyses that
controlled for order effects, a sufficient wash-out
period to minimize carry over, or both. Future
studies need to report how their design and
analyses have ensured that order and carry-over
effects have not contaminated the results.Conclusion
The studies in this review suggest that the wide-
spread prescription of short-burst oxygen is not
evidence-based. If prescription is to continue, the
scientific rationale for short-burst oxygen therapy
must be established in order to ensure the devel-
opment of an appropriate method of assessment.Acknowledgement
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